Table 3 Analysis of acute toxicity in sequential and integrated boost cohorts
Sequential boost | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
Dermatitis (n = 64) | 0% | 2% | 40% | 56% | 2% |
Mucositis (n = 63) | 3% | 8% | 19% | 68% | 2% |
Xerostomia (n = 60) | 12% | 53% | 33% | 2% | 0% |
Dysphagia (n = 65) | 3% | 5% | 37% | 55% | 0% |
Weight loss (n = 64) | −14.25 lbs. (−1.6– −32.8) | ||||
% Weight loss | 8.1% (0.8–23.0) | ||||
Simultaneous integrated boost | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
Dermatitis (n = 76) | 0% | 7% | 15% | 71% | 7% |
Mucositis (n = 73) | 1% | 3% | 14% | 79% | 3% |
Xerostomia (n = 70) | 0% | 56% | 44% | 0% | 0% |
Dysphagia (n = 75) | 0% | 1% | 17% | 79% | 3% |
Weight loss (n = 88) | −12.65 lbs. (+14.5– −33.0) | ||||
% Weight loss | 7.4% (0–18.3) | ||||